Lavipharm Group recorded a 24.1% increase in consolidated sales before clawbacks and rebates, while EBITDA from continuing operations rose by 5.2% in the first half of 2026. The results confirm… Lavipharm: Investments and acquisitions drive growth…
Lavipharm: Investments and acquisitions drive growth and international expansion
